ClinicalTrials.gg
CompletedNCT05258695Updated Oct 8, 2024

The Turkish Version of the AOFAS Hallux MTP-IP

An observational study in Foot Deformity, Hallux Deformity and Assessment, Self, sponsored by Istanbul University - Cerrahpasa. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Istanbul University - Cerrahpasa · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
66
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP) is originally developed in English to evaluate the pain, function and alignment in patients with hallux deformities. The purpose of this study is to translate and cross-culturally adapt the AOFAS Hallux MTP-IP scale into Turkish and investigate its psychometric properties.

Read the detailed description

The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP) is originally developed in English to evaluate joint function in patients with elbow stiffness. The purpose of this study is to translate and cross-culturally adapt the AOFAS Hallux MTP-IP scale into Turkish and investigate its psychometric properties. Approximately seventy patients with hallux deformities will be included. For cross-cultural adaptation, two bi-lingual translators will use the back-translation procedure. Within a 5-to-7-day period after the first assessment, the participants will complete the Turkish version of AOFAS Hallux MTP-IP (AOFAS Hallux MTP-IP-T) to evaluate test-retest reliability. Cronbach's alpha (α) will use to assess internal consistency. The correlation with the Turkish version of the Manchester-Oxford Foot Questionnaire (MOXFQ) and Short Form-12 will be determined to check the validity.

02

Conditions studied

  • Foot Deformity
  • Hallux Deformity
  • Assessment, Self
  • Orthopedic Disorder
03

In context

Foot Deformities

50 studies on the registry are indexed under Foot Deformities; 13 are open to participants now.

This study's enrollment of 66 is below the median of 84 across 22 observational studies indexed under Foot Deformities.

Browse Foot Deformities studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 699 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants are patients who have an hallux deformity and are treated in the orthopedic service. The participants with hallux deformity are directed for assessment following a confirmation by an orthopaedist based on the physical examinations and diagnostic imaging.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 65 years
  • Diagnosis of Hallux deformities
  • Continuing follow-up and treatment in the orthopedic service
  • Being able to follow simple instructions
  • Being able to read and write in Turkish

Exclusion criteria

Exclusion Criteria:

  • Having any cardiovascular diseases, neurological disorders, rheumatic diseases, or psychiatric diseases
  • Having peripheral nerve injury, peripheral neuropathy, or sensory loss in the lower extremity
  • Having heterotopic ossification, myositis ossification, or post-traumatic ankylosing in the lower extremity
  • Fracture, non-healing wound, or infection in the lower extremity
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
66 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP)

    The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP) is composed of 9 items, distributed over 3 categories: pain (40 points), functional aspects (50 points), and alignment (10 points), for a total of 100 points.

    Time frame: Day 1

Secondary outcomes

  1. The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP)

    The American Orthopedic Foot and Ankle Society hallux metatarsophalangeal-interphalangeal joint scale (AOFAS Hallux MTP-IP) is composed of 9 items, distributed over 3 categories: pain (40 points), functional aspects (50 points), and alignment (10 points), for a total of 100 points.

    Time frame: Within a 5-to-7-day period after the first assessment (Day 1)

  2. The Manchester-Oxford Foot Questionnaire (MOXFQ)

    The MOXFQ is a 16-item instrument answered on a five-point Likert scale (each item is scored from 0 to 4, with 4 denoting 'most severe'). Scores for each item are summed to form three separate subscales representing underlying domains: walking/standing problems (seven items), foot pain (five items), and issues related to social interaction (four items). Raw scale scores are then each converted to a metric from 0 to 100, where 100 denotes the most severe.

    Time frame: Day 1

  3. Short Form-12 (SF-12)

    Short Form-12 (SF-12), which is developed based on Short Form-36, consists of 12 items: 7 items dealing with the physical components scores (PCS-12) and 5 items related to the mental components scores (MCS-12) of SF-12. Range of both scores is 0 to 100, where the higher scores indicate better health related quality of life.

    Time frame: Day 1

  4. Visual Analogue Scale (VAS)

    Pain intensity will be measured using the Visual Analogue Scale (VAS), in which the participants will be asked to indicate their perceived pain at rest, during activity, and at night on the 10 cm line between no pain and terrible pain. The score will be determined by measuring the distance on a 10 cm line using a ruler.

    Time frame: Day 1

07

Study locations

1 site
  • Istanbul University-Cerrahpasa
    Istanbul, Bakırkoy 34147, Turkey
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Feb 28, 2022
StartActual
Jul 15, 2021
Primary completionActual
Oct 15, 2021
CompletionActual
Apr 11, 2022
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05258695
Responsible party
Tansu Birinci (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Feb 28, 2022
Start date
Jul 15, 2021
Primary completion
Oct 15, 2021
Completion
Apr 11, 2022
Last update
Oct 8, 2024

Study contacts

Tansu Birinci, PhD, PT
principal investigator · Istanbul University - Cerrahpasa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion